Robert Adam Arbuckle, MD
Neurology · San Diego
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 29
- 8 carriers
- Offices
- 3
Offices
3 locations · Southern California Permanente Medical Group · Neuranimus P C
Hospitals listed: Heart of the Rockies Regional Medical Center. That is not proof they admit you there this week.
Plans that list them
29 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Arbuckle’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
29 of 29 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A114731 · Current
Licensed to practise in California · since 2010 · expires 2028-08-31 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Colorado DR.60109Physician · since 2018 · expires 2027-04-30Specialty on the licence: NeurologyActiveNo board action on this licenceCheck it with the stateWhat they told the state about themselves
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- Neurology and Psychiatry
- Neurology and Psychiatry: Neuromuscular Medicine
Education
- New York University School of Medicine2009
What else the board holds
Hospitals they may admit to
Where the clinician told their state board they may admit and treat patients.
- Cedars Sinai · Los Angeles, CA
- Intermountain Health Good Samaritan Hospital · Lafayette, CO
- Intermountain Health Saint Joseph Hospital · Denver, CO
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
California
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Heart of the Rockies Regional Medical CenterSalida, COCritical Access Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Heart of the Rockies Regional Medical Center
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 1 the same, 0 worse of 1 measures. Readmissions: 1 better, 6 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 9.9 · 26 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13 · 34 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.8 · 46 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5 · 252 cases | None | Jul 2024 – Jun 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.761 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 50 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -52.2 · 46 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -38.6 · 46 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4 to 9.2) · 77 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.2 (6.3 to 13.1) · 77 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 25 cases | None | Jul 2023 – Jun 2025 |
What patients said (139 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 92% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 64% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$13,362
Medicare paid this office $13,362 for 59 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (60+ min) | 30 | $5,398 | $180 |
| Long return visit (40+ min) | 13 | $2,241 | $149 |
| Muscle electrical test | 14 | $2,068 | $80 |
Who their Medicare patients are
59 Original Medicare patients in 2024. Average age 75 · Women 54% · Also on Medicaid 31% · Health risk score 1.56. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 68% · Diabetes 36% · Coronary heart disease 36% · Chronic kidney disease 32% · Heart failure 27% · Stroke 24% · Atrial fibrillation 19% · Dementia 19%.
The office billed $37,294, Medicare allowed $17,363 and paid $13,362; for 98 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 59 | 98 | 75 | 1.56 | $37,294 | $13,362 |
| 2023 | 185 | 1,935 | 73 | 1.64 | $251,666 | $61,533 |
| 2022 | 213 | 2,447 | 74 | 1.77 | $342,680 | $80,453 |
| 2021 | 229 | 2,008 | 74 | 1.81 | $325,617 | $82,920 |
| 2020 | 153 | 2,356 | 73 | 1.75 | $212,809 | $49,323 |
| 2019 | 93 | 579 | 73 | 1.71 | $98,737 | $24,269 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Long return visit (40+ min) | 110 | $24,086 | $143 |
| New patient visit (60+ min) | 36 | $6,280 | $174 |
| Muscle electrical test | 37 | $5,737 | $86 |
| Nerve test | 18 | $4,420 | $246 |
| Return visit (30+ min) | 34 | $4,341 | $106 |
| Nerve test | 13 | $1,846 | $142 |
| Short return visit (20+ min) | 17 | $1,463 | $73 |
2022: 9 services
| Long return visit (40+ min) | 135 | $36,656 | $148 |
| New patient visit (60+ min) | 53 | $9,522 | $180 |
| Muscle electrical test | 38 | $4,924 | $91 |
| Nerve test | 17 | $4,470 | $263 |
| Return visit (30+ min) | 38 | $4,125 | $103 |
| Nerve test | 14 | $1,968 | $141 |
| Short return visit (20+ min) | 17 | $1,450 | $73 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $1,043 | $80 |
| Telephone medical discussion with physician, 5-10 minutes | 16 | $854 | $43 |
2021: 9 services
| Long return visit (40+ min) | 116 | $28,559 | $156 |
| New patient visit (60+ min) | 106 | $19,128 | $180 |
| Return visit (30+ min) | 53 | $6,031 | $96 |
| Muscle electrical test | 29 | $3,765 | $94 |
| Nerve test | 13 | $3,512 | $270 |
| Nerve test | 11 | $2,358 | $214 |
| Nerve test | 12 | $2,266 | $174 |
| Short return visit (20+ min) | 18 | $1,640 | $82 |
| Telephone medical discussion with physician, 5-10 minutes | 11 | $611 | $51 |
2020: 8 services
| Return visit (30+ min) | 57 | $8,650 | $89 |
| New patient visit (60+ min) | 50 | $8,478 | $170 |
| Nerve test | 22 | $4,910 | $223 |
| Muscle electrical test | 25 | $3,042 | $89 |
| Long return visit (40+ min) | 14 | $2,336 | $130 |
| New patient visit (45+ min) | 17 | $2,109 | $124 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $958 | $87 |
| Short return visit (20+ min) | 11 | $734 | $67 |
2019: 4 services
| New patient visit (60+ min) | 33 | $5,878 | $178 |
| Return visit (30+ min) | 32 | $3,444 | $91 |
| New patient visit (45+ min) | 18 | $2,284 | $127 |
| Muscle electrical test | 18 | $1,793 | $85 |
Drugs they prescribed that Part D paid
$11,026
Pharmacies billed $11,026 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 155) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
149 generic and fewer than 11 brand-name prescriptions · $11,026 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Levetiracetam | 19 | $540 | $28 |
| Gabapentin | 22 | $303 | $14 |
| Pregabalin | 12 | $138 | $12 |
Year by year
| 2024 | 155 | 75 | 0% (0) | None | $11,026 |
| 2023 | 831 | 173 | None | 20% | $548,165 |
| 2022 | 890 | 174 | 2% (16) | 13% | $496,606 |
| 2021 | 659 | 172 | 2% (12) | 11% | $180,323 |
| 2020 | 431 | 112 | None | 9% | $96,425 |
| 2019 | 433 | 138 | None | None | $144,828 |
| 2018 | 605 | 250 | None | 17% | $151,401 |
| 2017 | 815 | 217 | None | None | $131,814 |
| 2016 | 627 | 176 | None | None | $131,882 |
| 2015 | 493 | 148 | None | 14% | $142,363 |
| 2014 | 212 | 72 | None | 37% | $241,223 |
| 2013 | 59 | 19 | None | 59% | $138,880 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Gamunex-C | Immune globulin | 22 | $205,276 | $9,331 |
| Copaxone | None | 15 | $136,891 | $9,126 |
| Ampyra | None | 15 | $88,093 | $5,873 |
| Emgality | Migraine | 50 | $35,520 | $710 |
| Nurtec Odt | None | 15 | $17,762 | $1,184 |
| Ubrelvy | None | 12 | $11,420 | $952 |
| Memantine | None | 46 | $3,543 | $77 |
| Carbidopa-Levodopa | None | 44 | $3,039 | $69 |
| Gabapentin | None | 142 | $2,999 | $21 |
| Levetiracetam | None | 37 | $2,572 | $70 |
| Ropinirole | None | 16 | $1,622 | $101 |
| Pregabalin | None | 28 | $1,092 | $39 |
| Levetiracetam Er | None | 29 | $959 | $33 |
| Pyridostigmine | None | 14 | $725 | $52 |
| Quetiapine | None | 19 | $558 | $29 |
| Duloxetine | None | 14 | $537 | $38 |
| Nortriptyline | None | 12 | $498 | $41 |
| Sumatriptan | None | 17 | $366 | $22 |
| Propranolol | None | 27 | $362 | $13 |
| Donepezil | None | 16 | $185 | $12 |
| Topiramate | None | 22 | $183 | $8 |
2022: 21 drugs
| Copaxone | None | 21 | $162,087 | $7,718 |
| Gamunex-C | Immune globulin | 14 | $127,757 | $9,126 |
| Ampyra | None | 18 | $105,853 | $5,881 |
| Emgality | Migraine | 24 | $16,069 | $670 |
| Carbidopa-Levodopa | None | 85 | $7,138 | $84 |
| Memantine | None | 38 | $2,566 | $68 |
| Ropinirole | None | 22 | $1,998 | $91 |
| Gabapentin | None | 120 | $1,800 | $15 |
| Levetiracetam | None | 42 | $1,716 | $41 |
| Pregabalin | None | 35 | $1,654 | $47 |
| Levetiracetam Er | None | 33 | $1,368 | $41 |
| Rizatriptan | None | 19 | $937 | $49 |
| Nortriptyline | None | 22 | $595 | $27 |
| Propranolol | None | 23 | $511 | $22 |
| Donepezil | None | 33 | $390 | $12 |
| Sumatriptan | None | 21 | $322 | $15 |
| Topiramate | None | 24 | $270 | $11 |
| Cyclobenzaprine | None | 11 | $192 | $17 |
| Sertraline | None | 14 | $191 | $14 |
| Tramadol | None | 15 | $56 | $4 |
| Citalopram Hbr | None | 12 | $53 | $4 |
2021: 17 drugs
| Copaxone | None | 11 | $64,877 | $5,898 |
| Emgality | Migraine | 11 | $6,965 | $633 |
| Carbidopa-Levodopa | None | 76 | $4,634 | $61 |
| Levetiracetam Er | None | 41 | $2,041 | $50 |
| Memantine | None | 23 | $1,827 | $79 |
| Gabapentin | None | 108 | $1,547 | $14 |
| Zolmitriptan | None | 19 | $1,500 | $79 |
| Pregabalin | None | 13 | $1,070 | $82 |
| Levetiracetam | None | 27 | $928 | $34 |
| Ropinirole | None | 11 | $791 | $72 |
| Sumatriptan | None | 16 | $709 | $44 |
| Primidone | None | 15 | $687 | $46 |
| Propranolol | None | 11 | $446 | $41 |
| Tizanidine | None | 11 | $419 | $38 |
| Donepezil | None | 41 | $374 | $9 |
| Nortriptyline | None | 17 | $300 | $18 |
| Rizatriptan | None | 14 | $202 | $14 |
2020: 13 drugs
| Memantine | 17 | $1,443 | $85 |
| Levetiracetam Er | 13 | $1,088 | $84 |
| Carbidopa-Levodopa | 29 | $970 | $33 |
| Ropinirole | 15 | $858 | $57 |
| Gabapentin | 57 | $809 | $14 |
| Rivastigmine | 16 | $592 | $37 |
| Levetiracetam | 19 | $575 | $30 |
| Divalproex | 11 | $524 | $48 |
| Propranolol | 14 | $381 | $27 |
| Donepezil | 38 | $359 | $9 |
| Nortriptyline | 15 | $194 | $13 |
| Rizatriptan | 12 | $168 | $14 |
| Sumatriptan | 11 | $136 | $12 |
2019: 11 drugs
| Carbidopa-Levodopa | 34 | $1,846 | $54 |
| Levetiracetam | 39 | $1,510 | $39 |
| Pyridostigmine | 11 | $1,353 | $123 |
| Gabapentin | 41 | $1,004 | $24 |
| Propranolol | 19 | $926 | $49 |
| Zonisamide | 13 | $760 | $58 |
| Memantine | 12 | $682 | $57 |
| Donepezil | 30 | $452 | $15 |
| Baclofen | 11 | $397 | $36 |
| Topiramate | 15 | $315 | $21 |
| Lamotrigine | 13 | $195 | $15 |
2018: 18 drugs
| Carbidopa-Levodopa | 95 | $8,590 | $90 |
| Entacapone | 20 | $7,457 | $373 |
| Levetiracetam | 43 | $2,594 | $60 |
| Carbamazepine Er | 12 | $2,391 | $199 |
| Gabapentin | 53 | $1,978 | $37 |
| Mycophenolate Mofetil | 14 | $1,941 | $139 |
| Pyridostigmine | 13 | $1,907 | $147 |
| Propranolol | 26 | $1,603 | $62 |
| Carbidopa-Levodopa Er | 23 | $1,181 | $51 |
| Ropinirole | 19 | $734 | $39 |
| Lamotrigine | 24 | $684 | $29 |
| Primidone | 11 | $645 | $59 |
| Methylphenidate | 15 | $587 | $39 |
| Topiramate | 12 | $551 | $46 |
| Prednisone | 16 | $515 | $32 |
| Baclofen | 13 | $489 | $38 |
| Clopidogrel | 14 | $380 | $27 |
| Donepezil | 11 | $163 | $15 |
2017: 21 drugs
| Entacapone | 24 | $11,522 | $480 |
| Carbidopa-Levodopa | 103 | $10,945 | $106 |
| Lyrica | 11 | $10,319 | $938 |
| Carbidopa-Levodopa-Entacapone | 17 | $8,603 | $506 |
| Pyridostigmine | 18 | $5,967 | $331 |
| Levetiracetam | 62 | $3,802 | $61 |
| Gabapentin | 62 | $3,021 | $49 |
| Mycophenolate Mofetil | 13 | $2,170 | $167 |
| Carbamazepine | 16 | $2,066 | $129 |
| Carbidopa-Levodopa Er | 23 | $1,912 | $83 |
| Levetiracetam Er | 20 | $1,888 | $94 |
| Propranolol | 29 | $1,878 | $65 |
| Primidone | 25 | $1,503 | $60 |
| Ropinirole | 25 | $1,388 | $56 |
| Atorvastatin | 39 | $1,353 | $35 |
| Lamotrigine | 37 | $1,326 | $36 |
| Clopidogrel | 18 | $538 | $30 |
| Topiramate | 14 | $536 | $38 |
| Nortriptyline | 24 | $460 | $19 |
| Pravastatin | 11 | $373 | $34 |
| Clonazepam | 38 | $280 | $7 |
2016: 17 drugs
| Extavia | 11 | $33,616 | $3,056 |
| Entacapone | 14 | $7,900 | $564 |
| Carbidopa-Levodopa | 58 | $7,235 | $125 |
| Carbidopa-Levodopa-Entacapone | 13 | $5,216 | $401 |
| Gabapentin | 58 | $4,592 | $79 |
| Levetiracetam | 44 | $3,528 | $80 |
| Propranolol | 21 | $1,787 | $85 |
| Ropinirole | 27 | $1,470 | $54 |
| Primidone | 19 | $1,435 | $76 |
| Carbidopa-Levodopa Er | 14 | $1,297 | $93 |
| Lamotrigine | 30 | $1,249 | $42 |
| Atorvastatin | 21 | $764 | $36 |
| Prednisone | 13 | $658 | $51 |
| Topiramate | 12 | $585 | $49 |
| Nortriptyline | 25 | $483 | $19 |
| Lorazepam | 22 | $212 | $10 |
| Clonazepam | 21 | $172 | $8 |
2015: 14 drugs
| Gamunex-C | Immune globulin | 15 | $28,167 | $1,878 |
| Carbidopa-Levodopa | None | 53 | $5,657 | $107 |
| Gabapentin | None | 46 | $3,982 | $87 |
| Levetiracetam | None | 34 | $2,418 | $71 |
| Primidone | None | 14 | $1,086 | $78 |
| Ropinirole | None | 16 | $1,082 | $68 |
| Lamotrigine | None | 19 | $861 | $45 |
| Prednisone | None | 15 | $494 | $33 |
| Propranolol | None | 18 | $413 | $23 |
| Nortriptyline | None | 16 | $270 | $17 |
| Baclofen | None | 13 | $231 | $18 |
| Lorazepam | None | 18 | $192 | $11 |
| Clonazepam | None | 16 | $133 | $8 |
| Diazepam | None | 12 | $113 | $9 |
2014: 4 drugs
| Gammagard Liquid | Immune globulin | 14 | $111,379 | $7,956 |
| Gamunex-C | Immune globulin | 51 | $77,796 | $1,525 |
| Carbidopa-Levodopa | None | 16 | $1,585 | $99 |
| Gabapentin | None | 18 | $1,462 | $81 |
2013: 1 drug
| Gamunex-C | Immune globulin | 22 | $44,441 | $2,020 |
Money from drug and device companies
$182 in 2025
| 2025 | 2 | 3 | None | $182 |
| 2023 | 1 | 1 | None | $18 |
| 2022 | 1 | 2 | None | $30 |
| 2021 | 5 | 14 | None | $228 |
| 2020 | 3 | 4 | None | $78 |
| 2019 | 2 | 2 | $24 | $44 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 3 published payments
| Eisai | Meals · 2025-05-19 | Leqembi | $27 |
| Eisai | Meals · 2025-05-16 | Leqembi | $19 |
| Ucb | Meals · 2025-03-24 | Fintepla | $137 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $18
| AbbVie | Qulipta | $18 | 1 payment
|
2022: $30
| Novartis Pharmaceuticals | Kesimpta | $30 | 2 payments
|
2021: $228
| AbbVie | Ubrelvy | $128 | 8 payments
|
| Novartis Pharmaceuticals | Kesimpta | $50 | 3 payments
|
| Horizon Therapeutics plc | Uplizna | $20 | 1 payment
|
| Biohaven Pharmaceuticals | Nurtec Odt | $17 | 1 payment
|
| Amgen | Aimovig | $13 | 1 payment
|
2020: $78
| Allergan | Ubrelvy | $40 | 2 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $22 | 1 payment
|
| Teva Pharmaceuticals USA | Ajovy | $16 | 1 payment
|
2019: $44
| Acorda Therapeutics | Inbrija | $24 | 1 payment
|
| Novartis Pharmaceuticals | None | $20 | 1 payment
|
Professional record
- NPI
- 1659663136
- Licence
- CA A114731, CO DR.0060109California A114731: Current · expires 2028-08-31Colorado DR.60109: Active
- Trained
- New York University School of Medicine, 2009
- Group
- Southern California Permanente Medical Group · Neuranimus P C
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 10350 E Dakota Ave, Denver, CO, 80247
- NPI first listed
- 2011-05-03
- NPI last updated
- 2025-08-08
- NPI record certified
- 2025-08-08
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 10240 Park Meadows Dr, Lone Tree, CO, 80124 · 135 N Jackson Ave Ste 202, San Jose, CA, 95116
This office lists an electronic records connection.